CN101835492B - 用于制药应用的热动力学混合 - Google Patents

用于制药应用的热动力学混合 Download PDF

Info

Publication number
CN101835492B
CN101835492B CN2008801123533A CN200880112353A CN101835492B CN 101835492 B CN101835492 B CN 101835492B CN 2008801123533 A CN2008801123533 A CN 2008801123533A CN 200880112353 A CN200880112353 A CN 200880112353A CN 101835492 B CN101835492 B CN 101835492B
Authority
CN
China
Prior art keywords
tkc
ktz
compositions
polymer
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801123533A
Other languages
English (en)
Chinese (zh)
Other versions
CN101835492A (zh
Inventor
C·布拉夫
J·W·麦吉尼提
D·A·米勒
J·C·迪农齐奥
R·O·威廉姆斯三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austin Pharmaceutical Co ltd
University of Texas System
Original Assignee
Integrated Composite Material Corp
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrated Composite Material Corp, University of Texas System filed Critical Integrated Composite Material Corp
Publication of CN101835492A publication Critical patent/CN101835492A/zh
Application granted granted Critical
Publication of CN101835492B publication Critical patent/CN101835492B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801123533A 2007-08-21 2008-08-21 用于制药应用的热动力学混合 Active CN101835492B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95704407P 2007-08-21 2007-08-21
US60/957,044 2007-08-21
US5092208P 2008-05-06 2008-05-06
US61/050,922 2008-05-06
PCT/US2008/073913 WO2009026461A2 (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Publications (2)

Publication Number Publication Date
CN101835492A CN101835492A (zh) 2010-09-15
CN101835492B true CN101835492B (zh) 2012-11-21

Family

ID=40378995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801123533A Active CN101835492B (zh) 2007-08-21 2008-08-21 用于制药应用的热动力学混合

Country Status (6)

Country Link
US (6) US8486423B2 (enExample)
EP (1) EP2187968A4 (enExample)
JP (4) JP6073043B2 (enExample)
CN (1) CN101835492B (enExample)
CA (3) CA2990445C (enExample)
WO (1) WO2009026461A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246935B2 (en) 2016-05-13 2022-02-15 Merck Patent Gmbh Particle size and distribution of polymer for melt extrusion application

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP6073043B2 (ja) 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
DK2774608T3 (da) * 2008-06-16 2020-01-13 Pfizer Lægemiddelladede polymere nanopartikler og fremgangsmåder til fremstilling og anvendelse deraf
WO2010005725A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2012116238A1 (en) * 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
CN102204868B (zh) * 2011-05-18 2014-01-22 北京化工大学 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺
US9821283B1 (en) * 2011-07-25 2017-11-21 Dispersol Technologies, Llc Direct probe sensed temperature method for speed change for heat sensitive portions of a thermokinetically melt blended batch
MY179194A (en) 2012-09-17 2020-10-30 Pfizer Process for preparing therapeutic nanoparticles
US20150182457A1 (en) 2013-12-31 2015-07-02 Ascendia Pharmaceuticals, Llc Pharmaceutical Compositions For Poorly Water-Soluble Compounds
AP2016009494A0 (en) 2014-03-14 2016-10-31 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
EP3131667B1 (en) * 2014-04-18 2021-09-01 Dispersol Technologies, LLC Multiple speed process and mixer for preserving heat sensitive portions of a thermokinetically melt blended batch
US20170333404A1 (en) * 2014-11-03 2017-11-23 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
JP6730315B2 (ja) * 2015-01-20 2020-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体
WO2016205658A1 (en) 2015-06-17 2016-12-22 Dispersol Technologies, Llc Improved formulations of deferasirox and methods of making the same
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US20200009060A1 (en) * 2016-05-09 2020-01-09 Dispersol Technologies, Llc Improved drug formulations
JP7376220B2 (ja) * 2017-09-11 2023-11-08 オースティンピーエックス リミテッド ライアビリティ カンパニー 熱動力学的に溶融ブレンドされるバッチの熱感受性部分用の、直接プローブにより感知した温度による、速度変更のための方法
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF
CN109663524B (zh) * 2017-10-13 2022-07-15 分散技术有限责任公司 用于热动力学熔体共混批次的热敏部分的速度改变的直接进样探头感测温度方法
PT3470133T (pt) 2017-10-13 2020-12-15 Dispersol Technologies Llc Método de deteção de temperatura com sonda direta para mudança de velocidade para porções sensíveis ao calor de um lote fundido misturado termocineticamente
EP3706731A4 (en) * 2017-11-10 2021-08-18 Dispersol Technologies, LLC IMPROVED DRUG FORMULATIONS
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
WO2019125683A1 (en) * 2017-12-21 2019-06-27 Danisco Us Inc Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20220401579A1 (en) * 2019-11-30 2022-12-22 Dispersol Technologies, Llc Inclusion complexes of pharmaceuticals and cyclic oligomers
JP2023509385A (ja) * 2019-12-20 2023-03-08 エピザイム インコーポレイテッド Ｅｚｈ２阻害剤の結晶性ヒドロブロミド塩、その調製及びがんの治療に有用な医薬組成物
CN115515598A (zh) 2020-04-01 2022-12-23 德克萨斯大学系统董事会 氯硝柳胺的药物组合物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022125869A1 (en) * 2020-12-11 2022-06-16 Board Of Regents, The University Of Texas System Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2023010030A1 (en) * 2021-07-27 2023-02-02 Board Of Regents, The University Of Texas System Improved drug processing methods to increase drug loading
US20230112800A1 (en) 2021-08-31 2023-04-13 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CN119453203A (zh) * 2025-01-09 2025-02-18 山东百农思达生物科技有限公司 一种含杀虫单和阿维菌素的复合微乳制剂及其制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161588A (ja) * 2005-12-09 2007-06-28 Kotobuki Seiyaku Kk フェノフィブラートの固体分散体及びこれを含む高脂血症治療剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2319478A1 (fr) 1975-07-30 1977-02-25 Gen Electric Extrudeuse et procede d'extrusion de materiaux thermoplastiques
US4230615A (en) * 1978-11-21 1980-10-28 Carlew Chemicals Limited Process for controlled mixing in a high intensity mixer
US4628073A (en) 1984-10-03 1986-12-09 Monsanto Company Soft, rubbery, multiphase matrix material and methods for its production
US4789597A (en) 1987-01-12 1988-12-06 Fetherstonhaugh & Co. Incorporation of chemically reactive agents on resin particles
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH07159587A (ja) 1993-12-07 1995-06-23 Hitachi Ltd 樹脂性能モニタ
JPH07187998A (ja) * 1993-12-27 1995-07-25 Kao Corp 錠剤の製造方法
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5895790A (en) 1995-03-14 1999-04-20 Good; Elmer Thermosetting wide range polymer blends
DE19531067A1 (de) 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
AR028253A1 (es) 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US6709146B1 (en) 2000-07-28 2004-03-23 David Little Thermokinetic mixer and method of using
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
WO2004069138A2 (en) 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
DK1683524T3 (da) 2003-11-14 2011-03-14 Ajinomoto Kk Dispergering på fast form eller medicinsk præparat på fast form af phenyalaninderivat
US20050258288A1 (en) 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
JP2005263758A (ja) * 2004-03-22 2005-09-29 Kirin Brewery Co Ltd 非晶質のｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キナゾリニル）オキシ］フェニル｝−ｎ’−プロピルウレア
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
WO2006105196A2 (en) 2005-03-28 2006-10-05 Bioresponse, L.L.C. Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
JP2006347939A (ja) * 2005-06-15 2006-12-28 Tokyo Printing Ink Mfg Co Ltd 薬物高分子複合体の製造方法及び薬物高分子複合体
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
JP6073043B2 (ja) 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
JP2012047227A (ja) 2010-08-25 2012-03-08 Nippon Steel & Sumikin Metal Products Co Ltd ナット保持部材
WO2012116238A1 (en) 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
US20170333404A1 (en) 2014-11-03 2017-11-23 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161588A (ja) * 2005-12-09 2007-06-28 Kotobuki Seiyaku Kk フェノフィブラートの固体分散体及びこれを含む高脂血症治療剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246935B2 (en) 2016-05-13 2022-02-15 Merck Patent Gmbh Particle size and distribution of polymer for melt extrusion application

Also Published As

Publication number Publication date
EP2187968A2 (en) 2010-05-26
US20160250230A1 (en) 2016-09-01
JP2019052173A (ja) 2019-04-04
US20230172949A1 (en) 2023-06-08
US20180360850A1 (en) 2018-12-20
US11439650B2 (en) 2022-09-13
JP2010536877A (ja) 2010-12-02
US20130303630A1 (en) 2013-11-14
US8486423B2 (en) 2013-07-16
US9339440B2 (en) 2016-05-17
EP2187968A4 (en) 2013-02-20
CA3076115A1 (en) 2009-02-26
JP2016121195A (ja) 2016-07-07
CA2990445A1 (en) 2009-02-26
CA2697099A1 (en) 2009-02-26
WO2009026461A2 (en) 2009-02-26
US20090053315A1 (en) 2009-02-26
CA2990445C (en) 2020-05-05
US12023343B2 (en) 2024-07-02
US20200261473A1 (en) 2020-08-20
US10022385B2 (en) 2018-07-17
CA2697099C (en) 2018-02-20
CA3076115C (en) 2022-06-28
US10668085B2 (en) 2020-06-02
JP2014221816A (ja) 2014-11-27
WO2009026461A3 (en) 2009-04-30
CN101835492A (zh) 2010-09-15
JP6073043B2 (ja) 2017-02-01

Similar Documents

Publication Publication Date Title
CN101835492B (zh) 用于制药应用的热动力学混合
ES2699075T3 (es) Forma galénica farmacéutica que comprende una composición portadora polimérica
US20160193151A1 (en) Dosage form incorporating an amorphous drug solid solution
JP6491669B2 (ja) Ｃｇｒｐ活性化合物の錠剤製剤
JP6189429B2 (ja) ジエチルアミノエチルメタクリレートコポリマーをベースにした活性成分含有固体分散体
EP4008314A2 (en) Thermo-kinetic mixing for pharmaceutical applications
Patil A review on employing twin screw hot melt extrusion technology for the enhancement of the solubility profile of poorly aqueous-soluble APIs
DiNunzio et al. Polymeric interactions with drugs and excipients
Williams III et al. Thermo-kinetic mixing for pharmaceutical applications
Sandhu et al. Hot‐Melt Extrusion Technology for Modified‐Release (MR) Formulation Development
DiNunzio et al. Melt extrusion: pharmaceutical applications
Narala Novel Formulation Strategies With Hot-Melt Extrusion Technology to Address Physicochemical and Physiological Constraints for Improved Oral Drug Delivery
McGinity et al. Brough et al.
Hariharaputhraayyanar et al. AN EXTENSIVE REVIEW ON SUBLINGUAL MINITABLET OF RESPIRIDONE AND EVALUATION BY MELT-GRANULATION METHOD
Keen Novel formulations and thermal processes for bioavailability enhancement of soluble and poorly soluble drugs
US20230114357A1 (en) Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
Patel Dissolution Improvment of a Poorly Soluble Drug Using Hot Melt Extrusion Technique
Bello Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts
Alshetaili Solubility enhancement, mechanical properties and taste masking of poorly water soluble compounds by optimizing hot melt extrusion processing
PAUL MASTER OF PHARMACY
Dahiya et al. INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
Singh Design and development of drug delivery systems for immediate and sustained release utilizing hot melt extrusion
rights are reserved by Kharde et al. Formulation and Evaluation of Fast Disintegrating Tablet of Carvedilol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DESPAIGNE SPEED TECHNOLOGY LTD.

Free format text: FORMER OWNER: INTEGRATED COMPOSITE MATERIAL CORPORATION

Effective date: 20150422

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150422

Address after: Texas, USA

Patentee after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee after: Despain Speed Technology Co.,Ltd.

Address before: Texas, USA

Patentee before: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee before: INTEGRATED COMPOSITE MATERIAL Corp.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Texas, USA

Patentee after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee after: Austin Pharmaceutical Co.,Ltd.

Address before: Texas, USA

Patentee before: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee before: Despain Speed Technology Co.,Ltd.